Dr Reddy’s Laboratories Limited announced the launch of Remdesivir on Wednesday, under the brand name of ‘Redyx’ for the treatment of COVID-19 patients in India.

According to a press release organized by the drug maker, the launch is a part of the licensing agreement with Gilead (Gilead Sciences, Inc.) which will grant the rights to Dr Reddy’s for registering, manufacturing and selling Remdesivir, as a potential treatment for Covid-19 patients, in about 127 countries including India. The Drug Controller General of India (DCGI) approved Remdesivir for the restricted emergency use in India and the treatment of hospitalized Covid-19 patients with severe symptoms.

It said, “Dr Reddy’s Redyx is available in the strength of 100 mg vial”. M V Ramana, CEO & Head of Branded Markets, DR Reddy’s Laboratories Ltd., said, “We will continue our efforts to develop products that address significant unmet needs of patients.

The launch of Redyx reaffirms our commitment to bringing in critical medicine for patients suffering from COVID-19 in India.”